300 New Molecular Entities (NMEs) are expected to be approved in 2022-2026*.
26 Dec 2022, 13:00
300 New Molecular Entities (NMEs) are expected to be approved in 2022-2026*.
The influx of NMEs demonstrates the need for reliable & cost-efficient clinical trials.
Triall's software platform supports all therapeutic areas, trial types & trial phases.
*Source: IQVIA Institute
Same news in other sources
2
26 Dec 2022, 13:25
🔍 Fact of the day 🔍
According to the IQVIA Institute, 300 new molecular entities (‘NMEs’) are expected to be approved between 2022 and 2026. This translates into 60 NMEs per year compared to the 53 NMEs per year average over the past decade.
The influx of NMEs demonstrates the need for specialised service providers who can help perform reliable and cost-efficient clinical trials.
Triall’s eClinical platform is designed to support any therapeutic area, any trial type (decentralized, hybrid, site-based), and any trial phase (I-IV). We offer a modular and fully-integrated suite of software solutions that can be configured to specific needs and budgets.
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help us spread the news on Twitter:
#blockchainforhealth #TRL
Fact of the day.
🔍 Fact of the day 🔍
According to the IQVIA Institute, 300 new molecular entities (‘NMEs’) are expected to be approved between 2022 and 2026. This translates into 60 NMEs per year compared to the 53 NMEs per year average over the past decade.
The influx of NMEs demonstrates the need for specialised service providers who can help perform reliable and cost-efficient clinical trials.
Triall’s eClinical platform is designed to support any therapeutic area, any trial type (decentralized, hybrid, site-based), and any trial phase (I-IV). We offer a modular and fully-integrated suite of software solutions that can be configured to specific needs and budgets.
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1607360580934852608?s=20&t=Ty8KS4aJh9V6j9U0a5Nn8w
#blockchainforhealth #TRL
26 Dec 2022, 13:25
🔍 Fact of the day 🔍
According to the IQVIA Institute, 300 new molecular entities (‘NMEs’) are expected to be approved between 2022 and 2026. This translates into 60 NMEs per year compared to the 53 NMEs per year average over the past decade.
The influx of NMEs demonstrates the need for specialised service providers who can help perform reliable and cost-efficient clinical trials.
Triall’s eClinical platform is designed to support any therapeutic area, any trial type (decentralized, hybrid, site-based), and any trial phase (I-IV). We offer a modular and fully-integrated suite of software solutions that can be configured to specific needs and budgets.
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help us spread the news on Twitter:
#blockchainforhealth #TRL
Fact of the day.
🔍 Fact of the day 🔍
According to the IQVIA Institute, 300 new molecular entities (‘NMEs’) are expected to be approved between 2022 and 2026. This translates into 60 NMEs per year compared to the 53 NMEs per year average over the past decade.
The influx of NMEs demonstrates the need for specialised service providers who can help perform reliable and cost-efficient clinical trials.
Triall’s eClinical platform is designed to support any therapeutic area, any trial type (decentralized, hybrid, site-based), and any trial phase (I-IV). We offer a modular and fully-integrated suite of software solutions that can be configured to specific needs and budgets.
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1607360580934852608?s=20&t=Ty8KS4aJh9V6j9U0a5Nn8w
#blockchainforhealth #TRL